Kathleen M Metters

Dr Metters has over 25 years of experience in the discovery and development of novel therapies for treatment of diseases. She is currently working as an independent biopharma consultant and as senior advisor for New York-based Bridge Medicines. From 2011-2014 Dr Metters was President and Chief Executive officer for Lycera Corp. Dr Metters is currently a board member of HemoShear Therapeutics, LLC. From 1988 to 2011 Dr Metters was employed by Merck & Co. In 2009 she was appointed to design and establish External Discovery and Preclinical Sciences. From 2005 to 2009 Dr Metters was head of Worldwide Basic Research for Merck & Co. From 2002 to 2005 Dr Metters was head of Merck Frosst which under her leadership, additional compounds were moved into clinical development for treatment of respiratory, cardiovascular and bone disorders. During this time, she was the Basic Research Therapeutic Area Head for the Respiratory Franchise and from 2003-2005 was chair of the Respiratory Worldwide Business Strategy Team, reporting directing to the CEO, with responsibility for the discovery, development and commercialization strategy for all respiratory products. Prior to that Dr Metters worked in research on the arachidonic acid cascade which resulted in the development of SINGULAIR.